RETROSPECTIVE ANALYSIS OF DIAGNOSTIC IMAGES OF LYMPHOPROLIFERATIVE DISORDERS
DOI:
https://doi.org/10.32782/2226-2008-2024-1-3Keywords:
lymphoproliferative diseases, computer tomography, lymph nodes, gastrointestinal tract, spleenAbstract
The analysis is aimed at comparing the results of independent studies of the radio tomographic picture of lymphoproliferative diseases with different localization of the pathological process and the experience of leading international organizations studying the diagnostic criteria of various types of lymphomas, such as the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), EORTS, and ASCO, which allow diagnosing lymphoproliferative diseases and planning therapy based on the interpretation of PET/ CT and contrast-enhanced CT data (assessment of treatment effectiveness on a 5-point Deauville scale). The analysis is based on the results of original studies of 156 patients with lymphomas of various localization, including lymph nodes, gastrointestinal tract, spleen, pancreas, kidneys, adrenal glands, etc. Lymphomas are malignant neoplasms arising from mature lymphocytes. The incidence of Hodgkin’s lymphoma in Ukraine is approximately 2.4 cases per 100,000 population. Lymphomas are classified according to the 2022 WHO classification of tumors of hematopoietic and lymphoid tissues based on the cells of origin. At the same time, radio tomographic examination reveals characteristic features of lymphoproliferative diseases: thickening of organ walls, wall deformation, presence of lymphadenopathy, and others. The specifics of organ involvement are highlighted, emphasizing the importance of PET/CT and contrast-enhanced CT as diagnostic and staging tools, as well as for monitoring the course and effectiveness of treatment of lymphoproliferative diseases.
References
Gaillard F, Jones J, Feger J, et al. Lymphoma. Radiopaedia.org. [Internet]. Available from: https://doi.org/10.53347/rID-9229. Accessed 13 Sep 2023.
Cheson B.D., Fisher R.I., Barrington S.F. et al. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano. assification. J. Clin. Oncol., Aug. 11. pii: JCO.2013.54.8800.
Chernobai TN, Holovko TS Promeneva diahnostyka ekstranodalnykh limfom. Klinichna onkolohiia. 2017; 4(28).
Kriachok IA, Novak VL, Zaho NA Diahnostyka y likuvannia limfomy Khodzhkina: suchasni standarty ta perspektyvy rozvytku. Konferentsiia ONKOHEMATOLOHIIa. Tematychnyi nomer; Liutyi 2017. S. 20–21.
Dr. med. Petra Mehling, Inga Haas + 20., Hodgkin-Lymphom, Available from: https://flexikon.doccheck.com/de/Hodgkin-Lymphom Letzter Edit: 17.01.2023,
Zinzani PL, Ramchandren R, Santoro A et al.: Phase 3, randomized, open-label study of Pembrolizumab (Pembro) versus Brentuximab Vedotin (BV) for treatment of relapsed or refractory classical Hodgkin Lymphoma (r/r cHL): Keynote-204. EHA25 Virtual Meeting, EHA Library. Zinzani P. 06/12/20; 303389; LB2600
Aldin, A., L. Umlauff, L. J. Estcourt, G. Collins, K. G. M. Moons, A. Engert, C. Kobe, B. von Tresckow, M. Haque, F. Foroutan, and et al.. 2020. 'Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of prognostic factor studies', Cochrane Database of Systematic Reviews.
Testimonial email from the Scientific Advisor at Lymphoma Research Foundation (USA), 17th June 2020 [PDF]
Testimonial email from the Chair of the National Cancer Research Institute’s Hodgkin Lymphoma Research Group, 17th June 2020 [PDF]
You tube video from New England Journal of Medicine describing outcomes from the RATHL trial with 27,401 views last accessed 18/01/2021 [PDF]
Hodgkin Lymphoma: – Pages 50,53 refer to treatment approach tested in RAPID trial and pages 53,55; page 52 refers to RATHL trial now in routine clinical practice. Last accessed 18/01/2021. [PDF]
Testimonial from the Head of Department of Haematology at Concord Hospital, University of Sydney 27th January 2021 [PDF]
Lymphoma Action Patient Conference presentation by Dr MacKay from University of Glasgow discussing RAPID and RATHL and how they are used in clinical practice slides, 15-23 September 2018. Last accessed 18/01/2021 [PDF]
Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. – DOI – PubMed
Faryal Munir 1, Viney Hardit 2, Irtiza N Sheikh 1, Shaikha AlQahtani 1, Jiasen He 1, Branko Cuglievan 1 3, Chitra Hosing 4, Priti Tewari 2, Sajad Khazal 2, Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances, Int J Mol Sci. 2023 Jun 13;24(12):10095. doi: 10.3390/ijms241210095.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014) Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32 (27): 3048-58. doi:10.1200/JCO.2013.53.5229 – Pubmed
Kharuzhyk S.A., Zhavrid E.A., Dziuban A.V., Sukolinskaja E.V., Kalenik O.A. Comparison of the diagnostic effectiveness of whole body magnetic resonance imaging with diffusion weighted imaging and positron emission tomography/computed tomography in determining tumor response in lymphoma after the end of chemotherapy: Minsk scaleand Deauville scale. Diagnostic radiology and radiotherapy. 2020;11(1):78-92. (In Russ.) Available from: https://doi.org/10.22328/2079-5343-2020-11-1-78-92
